• Nautilus Biotechnology entered an at-the-market equity distribution agreement with TD Securities (USA) to sell up to USD 125 million of common stock.
• TD Securities will act as sales agent. Fees set at up to 3% of gross proceeds on shares sold.
• Program replaces a prior TD Cowen ATM agreement dated Feb. 28, 2024, which was mutually terminated. No shares were sold under it.
• Sales can begin once the company’s Form S-3 shelf registration statement is declared effective by the SEC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001808805-26-000041), on September 11, 2026, and is solely responsible for the information contained therein.